Mats Blom has become chief financial officer at the Dutch biotech NorthSea Therapeutics BV which is developing treatments for metabolic and fibrotic diseases including nonalcoholic steatohepatitis (NASH). Mr Blom was previously CFO at Zealand Pharma A/S where he oversaw the company’s listings on Nasdaq OMX Copenhagen and Nasdaq Global Markets in New York. Prior to this, he was CFO at Swedish Orphan International which is now part of Swedish Orphan Biovitrum.
Mr Blom earned an MBA from the IESE Business School in Barcelona, Spain and holds a bachelor’s degree in business administration from Lund University in Sweden.
NorthSea Therapeutics announced the appointment on 4 September 2019.
Copyright 2019 Evernow Publishing Ltd.